Carol Abel joins FMI as VP education and research
ARLINGTON, Va. A former executive at the American Pharmacists Association has joined the Food Marketing Institute to develop and execute the organization’s education programs and research initiatives.
Carol Abel was named FMI’s VP education and research. Abel comes to FMI from the American Pharmacists Association where she most recently served as senior director of education strategy and compliance officer. She was responsible for the association’s pharmacy accreditation program, continuing education best practices, standards and new initiatives. She also served as director of education for the association.
“As provided in the new FMI strategic plan approved earlier this year by the board of directors, we are laser-focused on enhancing our industry education programming and expanding opportunities in leadership development for those who work in our member companies,” said FMI president and CEO Leslie Sarasin. “Carol has an impressive background and extensive expertise, and her previous success in identifying innovative educational strategies makes her a welcome addition to the FMI team.”
CHPA names new president
WASHINGTON Scott Melville now is at the helm of the Consumer Healthcare Products Association.
CHPA said Tuesday that Melville, who currently serves as SVP government affairs and general counsel for the Healthcare Distribution and Management Association, will succeed Linda Suydam as president, who is retiring after eight years with CHPA.
Melville brings more than two decades of healthcare, legislative, regulatory and association management experience to his new role as CHPA president. Prior to joining HDMA, the national association representing pharmaceutical wholesale distributors, Melville served as an attorney and head of government relations for Cephalon.
“I am extremely honored to join CHPA at this critical time and to build upon the many accomplishments realized under Linda Suydam’s leadership,” Melville said. “I look forward to working with the CHPA board and the entire membership to further advance the essential contribution that [over-the-counter] medicines and dietary supplements offer to millions of American consumers seeking safe, effective and convenient healthcare remedies.”
Sun Pharma gets FDA approval for ALS generic
MUMBAI, India The Food and Drug Administration has approved a generic version of a drug for a devastating muscular disorder.
Sun Pharmaceutical Industries announced Tuesday the approval of riluzole hydrochloride in the 50-mg strength. The tablets are used to treat amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease.
The drug is a generic version of Sanofi-Aventis’ Rilutek, which has sales of around $50 million, according to Sun.